The Effect of Polycystic Ovarian Syndrome Treated with Combined Oral Contraceptives on Female Lipid Profiles
Polycystic ovarian syndrome is the most common endocrine disease of women in reproductive age frames, affecting around 5-10% of premenopausal women. The utilization of combined oral contraceptives, containing both estrogen and progestin-like compounds, is the most common treatment of polycystic ovarian syndrome among these women. Polycystic ovarian syndrome symptoms tend to cause elevated levels of overall cholesterol, specifically low density lipoprotein while also increasing androgen secretion and circulation throughout the body. Conversely, combined oral contraceptives have effects of lowering androgen levels and decreasing overall cholesterol levels. The effects of combined oral contraceptives on lipid profiles in women with polycystic ovarian syndrome is newly studied due to the complexities of the pharmacological intervention and disease presentation. Due to the prevalence of polycystic ovarian syndrome and the use of combined oral contraceptives in premenopausal women, it is necessary to understand the relation between the two and the general effects on the body.